Methods of reducing angiogenesis
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsJohn Cooke, Christopher Heeschen, Michael Weis
Life of this patent
Estimating the term…
Abstract
The present invention provides methods of reducing angiogenesis in an individual. The methods generally involve administering to the individual an effective amount of a nicotinic acetyl choline receptor antagonist. The methods are useful to treat conditions associated with or resulting from angiogenesis, particularly pathological angiogenesis. The invention further provides methods of treating a condition associated with or resulting from angiogenesis.
Claims14
A method of reducing angiogenesis in a mammal, the method comprising administering to a mammal a nicotinic acetylcholine receptor (nAChR) antagonist in an amount effective to reduce angiogenesis.
A method of treating a disorder associated with pathological angiogenesis, the method comprising administering to a mammal a nicotinic acetylcholine receptor (nAChR) antagonist in an amount effective to reduce pathological angiogenesis.
A method of inhibiting tumor growth in a mammal, the method comprising administering to a mammal having a tumor a nicotinic acetylcholine receptor (nAChR) antagonist in an amount effective to reduce angiogenesis, wherein said administering is peritumoral, and wherein a reduction in angiogenesis inhibits tumor growth.
A method of inhibiting abnormal fibrovascular growth in a mammal, the method comprising administering to a mammal having abnormal fibrovascular growth a nicotinic acetylcholine receptor (nAChR) antagonist in an amount effective to reduce abnormal fibrovascular growth in the mammal.
A method of inhibiting a proliferative retinopathy in a mammal, the method comprising administering to a mammal having a tumor a nicotinic acetylcholine receptor (nAChR) antagonist in an amount effective to reduce the proliferative retinopathy in the mammal.
A method of inhibiting pathological neovascularization associated with a tumor, the method comprising administering to a mammal having a tumor a nicotinic acetylcholine receptor (nAChR) antagonist in an amount effective to reduce the tumor-associated pathological neovascularization in the mammal.
Dependencies are inferred from the claim text.